Stranded Technologies Podcast · Infinita City

Ep. 90: Unlimited Bio’s Journey to Launch a Prospera Biotech Company - with Ivan Morgunov & Dr. Anna Vakhrusheva

February 19, 2025·1 hr 4 min·4 clips

Unlimited Bio chose a VEGF plasmid therapy and licensed it from a Russian company for preventive use.

1. Stranded Technologies Podcast episode 90 centers on Unlimited Bio's attempt to launch a Prospera biotech company built around gene therapies for longevity. 2. Ivan Morgunov is the CEO, Dr. Anna Vakhrusheva is the CTO, and both matter because they combine biotech execution with longevity R&D experience. 3. The episode asks what it takes to move aging interventions from research into human use faster than classical regulation allows. 4. Ivan says he came from high-tech and entrepreneurship, then moved into longevity biotech because he wanted to contribute to solving aging during his lifetime. 5. Anna says she was drawn to aging, genomics, and genetic anomalies from school and later studied biochemistry, molecular biotechnology, and bioengineering. 6. Anna says she co-founded Betavax and helped develop a COVID vaccine in about two years, which she contrasts with the usual 10-year biotech timeline. 7. Ivan says the longevity field is held back by over-regulation, long development cycles, and the need to wait for disease before treatment. 8. He uses cancer as an example, saying the system often waits for illness and then uses toxic chemotherapy instead of preventive intervention. 9. Ivan says one drug per target is too limited, and he compares aging to a melody that needs many piano keys played together. 10. Anna says biomarkers are another bottleneck, and she criticizes epigenetic clocks as too variable to correlate reliably with clinical outcomes. 11. Anna also says recruiting healthy participants is hard because they do not feel immediate risk from aging, even when the therapies are meant to prevent future disease. 12. Ivan says the field needs faster, cheaper development and cites the Pareto principle as a way to focus on the bottlenecks that matter most. 13. Anna says longevity therapies also face manufacturing costs, quality control requirements, and the need to determine dose in healthy individuals through trials. 14. Ivan says the company used a Prospera documentary and the Vitalia environment to learn how the regulatory system worked before starting Unlimited Bio. 15. He says they met people including Christian, Tristan Robert, and Bojang, and that those conversations helped them understand clinical and legal steps quickly. 16. Ivan says they chose VEGF gene therapy as a simple MVP, licensed it from a Russian company, and aimed to repurpose it for preventive use. 17. The tone is practical and procedural, with the hosts pressing on regulation, manufacturing, and trial design rather than abstract longevity theory. 18. The conversation also feels collaborative and technical, with Ivan and Anna correcting each other and filling in different parts of the story. 19. People interested in longevity biotech, gene therapy, and regulatory strategy would likely follow this closely. 20. People looking for a general science explainer without startup and regulation detail may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Stranded Technologies Podcast